Amanda Cimsit, MD
Colon & Rectal Surgery · Boston, MANPI 1750565693
Payments from drug & device makers
What this record shows
This record is dominated by education: $24,000 of the $24,651 with a category attached, or 97.4%. Intuitive Surgical accounts for 99.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $18,110 and has fallen 99.8% since, to $36 in 2024.
Across 21 payments — averaging $1173.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$24K
- Takeda Pharmaceuticals U.S.A., Inc.$117
- Axonics, Inc.$29
- Polynovo North America LLC$27
- Acera Surgical, Inc.$20
- Integra Lifesciences Corporation$19
- plus $31 from 2 others
What the payments were for
- Travel & lodging$2521%
- Food & beverage$3992%
- Education$24,00097%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $24,409 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $117 |
| Axonics, Inc. | 1 | $29 |
| Polynovo North America LLC | 1 | $27 |
| Acera Surgical, Inc. | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $19 |
| Conmed Corporation | 1 | $16 |
| Baudax Bio Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$18,000
- Da Vinci Surgical System$6,359
How this compares
$24,651 in reported general payments places this provider in the 75th percentile of 49 colon & rectal surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $293 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $203 |
| Neomycin Sulfate | 29 | $170 |
| Metronidazole | 28 | $76 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Boston
- Patricia SyllaBoston$139K
- Lilian ChenBoston$48K
- Jennifer DavidsBoston$36K
- Deborah NagleBoston$33K
- Olga BeresnevaBoston$30K
- Robert GoldstoneBoston$22K
- Melissa MurphyBoston$13K
- Hiroko KunitakeBoston$11K
- James YooBoston$8K
- Jennifer IraniBoston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.